Cadrenal Therapeutics

CVKD48

High Growth

$15.66arrow_drop_down5.49%-$0.91

High Growth

CVKD48

$15.66

arrow_drop_down5.49%-$0.91

High Growth

Performance History

Key Stats
Open	$17.25
Prev. Close	$16.57
EPS	-6.73
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$23.43M
PE Ratio	-

	LOW	HIGH
Day Range	15.48	17.26
52 Week Range	5.40	32.55

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-6.73

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Cadrenal Therapeutics (CVKD)

Cadrenal Therapeutics, Inc. (CVKD) is a biotechnology company that focuses on the development of novel therapeutics for cardiovascular and kidney diseases. The company's mission is to improve the lives of patients suffering from these conditions by providing innovative treatment options. With a strong commitment to research and development, Cadrenal Therapeutics is at the forefront of cutting-edge science in the field of cardiovascular and kidney diseases. The company's research team is composed of leading experts in the field, who are dedicated to finding new ways to treat and prevent these debilitating diseases.

One of the key factors that sets Cadrenal Therapeutics apart from its competitors is its proprietary technology platform. The company's platform allows for the rapid identification and optimization of potential drug candidates, greatly accelerating the drug development process. This technology has already yielded promising results, with several potential drug candidates showing strong efficacy and safety profiles in preclinical studies. Cadrenal Therapeutics is currently advancing these candidates into clinical trials, with the goal of bringing them to market as soon as possible.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Quang X. Pham
Headquarters: Ponte Vedra
Employees: 3
Exchange: NASDAQ

Keep an eye on Cadrenal Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Cadrenal Therapeutics's (CVKD) price per share?

The current price per share for Cadrenal Therapeutics (CVKD) is $15.66. The stock has seen a price change of -$0.91 recently, indicating a -5.49% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Cadrenal Therapeutics (CVKD)?

For Cadrenal Therapeutics (CVKD), the 52-week high is $32.55, which is 107.85% from the current price. The 52-week low is $5.4, the current price is 190% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Cadrenal Therapeutics (CVKD) a growth stock?

Cadrenal Therapeutics (CVKD) has shown an average price growth of -6.65% over the past three years. It has received a score of 100 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cadrenal Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Cadrenal Therapeutics (CVKD) stock price performance year to date (YTD)?

As of the latest data, Cadrenal Therapeutics (CVKD) has a year-to-date price change of 57.28%. Over the past month, the stock has experienced a price change of 2.02%. Over the last three months, the change has been 134.66%. Over the past six months, the figure is 142.73%.

help

Is Cadrenal Therapeutics (CVKD) a profitable company?

Cadrenal Therapeutics (CVKD) has a net income of -$8.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$7.63M. Furthermore, the EBITDA is -$6.63M.

help

What is the market capitalization of Cadrenal Therapeutics (CVKD)?

Cadrenal Therapeutics (CVKD) has a market capitalization of $25.98M. The average daily trading volume is 16.16, indicating the stock's liquidity and investor engagement.